The Serum Institute of India (SII), which produces the AstraZeneca COVID-19 vaccine, will resume small exports via the global vaccine-sharing platform COVAX this month and raise it substantially by January 2022, its head has said.
“Our exports to COVAX will recommence again in October, initially these supplies will be small but by January 2022, once we have satisfied domestic demands – people forget that India is still a lower-middle income country – we will see large volumes go to COVAX,” Adar Poonawalla, Chief Executive, SII, said.